Myotonic Dystrophy Type 1 (DM1) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Myotonic Dystrophy Type 1 (DM1) Market Outlook Thelansis’s “Myotonic Dystrophy Type 1 (DM1) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myotonic Dystrophy Type 1 (DM1) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Myotonic Dystrophy Type 1 (DM1) Overview Myotonic Dystrophy Type 1 (DM1) is a multisystemic, autosomal dominant disorder caused by an unstable expansion of a CTG trinucleotide repeat in the 3′ untranslated region of the DMPK gene on chromosome 19q13.3, which encodes the dystrophia myotonica protein kinase. The condition affects skeletal and smooth muscle, as well as ocular, cardiac, endocrine, an...